Full-Time
Introduce Yourself: Send us your Resume
Posted on 10/23/2024
2seventy Bio
51-200 employees
Develops novel cancer therapies via R&D
No salary listed
Cambridge, MA, USA + 1 more
More locations: Seattle, WA, USA
In Person
 Lab & Research (1) |
|---|
- Time management
- Ability to work in a fast-paced, motivated culture
- Alignment with mission to offer patients and families more time
- Willingness to submit resume for future openings
- Not explicitly listed in the posting
- Not explicitly listed in the posting
2seventy bio develops cancer therapies by applying expertise in cancer cell biology, genetics, and the immune response to create treatments that can alter the cancer treatment landscape. Their products are advanced cancer therapies that advance through discovery, research and development, clinical trials, and regulatory approval before being sold or partnered for commercialization. Unlike many competitors, they emphasize rapid translation of science into therapies and pursue collaborations with other pharmaceutical companies to accelerate bringing therapies to patients. The company aims to give people more time to enjoy life by extending survival and improving quality of life for individuals diagnosed with cancer.
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2021
Your Connections
People at 2seventy Bio who can refer or advise you
Simplify's Take
What believers are saying
- Abecma triples progression-free survival versus standard regimens in KarMMa-3 trial.
- FDA expanded Abecma label in April 2024 to earlier multiple myeloma lines.
- Bristol Myers Squibb agreed to acquire 2seventy bio for $286 million.
What critics are saying
- Regeneron discontinued bbT369 CAR T during phase 1/2 lymphoma trial.
- Abecma sales stagnate below $242 million due to Carvykti competition.
- Grade 3/4 thrombocytopenia hits 62% at high Abecma doses.
What makes 2seventy Bio unique
- 2seventy bio focuses exclusively on Abecma commercialization post-Regeneron divestiture.
- Abecma targets BCMA for triple-class exposed multiple myeloma after FDA's April 2024 approval.
- CBLB gene-edited CAR T platform enhanced bbT369's T cell activity in preclinical B-NHL models.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Wellness Program
Mental Health Support
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
PTO/vacation
Hybrid Work Options
401(k) Retirement Plan
401(k) Company Match
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Family Planning Benefits
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 3%2 year growth
↓ -4%2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all
March 11 (Reuters) - Bristol Myers Squibb (BMY.N) will acquire 2seventy bio (TSVT.O) for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming TD Cowen 45th Annual Healthcare Conference on March 5, 2025 at 11:10 a.m. ET in Boston, Mass.A live webcast of the fireside chat will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. Replays will be archived on 2seventy bio’s site for 30 days following the event.About 2seventy bioOur name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible
Bristol Myers has acquired its cell therapy partner, 2seventy bio. The article does not provide specific financial details about the acquisition.
In addition, 2seventy bio recently appointed Jessica Snow as its new Chief Operating Officer.